Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969130 | 0.81 | PRMT1 (0.47) | PRMT1PARP1TMEM97SIGMAR1MEN1 | |
| SCHEMBL21320989 | 0.74 | PRMT1 (0.53) | PRMT1 | |
| SCHEMBL21321036 | 0.72 | PRMT1 (0.45) | PRMT1 | |
| SCHEMBL21320996 | 0.71 | PRMT1 (0.43) | PRMT1 | |
| SCHEMBL21321275 | 0.70 | PRMT1 (0.46) | PRMT1 | |
| SCHEMBL21321197 | 0.69 | PRMT1 (0.51) | PRMT1 | |
| SCHEMBL21315224 | 0.66 | PRMT1 (1.00) | PRMT1 | |
| SCHEMBL20451406 | 0.65 | TMEM97 (0.41) | PARP1TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL30802045 | 0.65 | SIGMAR1 (0.48) | PARP1TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL30802046 | 0.65 | SIGMAR1 (0.48) | PARP1TMEM97SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416261-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | UNIV TEXAS (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2022192527-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416261-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT7, PRMT5 | PRMT1 1/4885PARP1 479/4885PTGDR2 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.